Back to top
more

Verrica Pharmaceuticals (VRCA)

(Real Time Quote from BATS)

$6.67 USD

6.67
102,489

-0.38 (-5.39%)

Updated Jul 30, 2024 03:30 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (103 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

KemPharm (KMPH) Stock Up on Deal to Acquire Orphazyme for $12.8M

by Zacks Equity Research

KemPharm (KMPH) inks deal to acquire Orphazyme A/S, which will add to its portfolio the latter's pipeline candidate, arimoclomol, being developed for treating Niemann-Pick disease type C. Shares rise.

After Plunging 28.5% in 4 Weeks, Here's Why the Trend Might Reverse for Verrica Pharmaceuticals Inc. (VRCA)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Verrica Pharmaceuticals Inc. (VRCA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Here's Why Verrica Pharmaceuticals Inc. (VRCA) is Poised for a Turnaround After Losing 31.6% in 4 Weeks

by Zacks Equity Research

The heavy selling pressure might have exhausted for Verrica Pharmaceuticals Inc. (VRCA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Does Verrica Pharmaceuticals Inc. (VRCA) Have the Potential to Rally 60% as Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for Verrica Pharmaceuticals Inc. (VRCA) points to a 59.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Ekta Bagri headshot

Biotech Stock Roundup: Regulatory Updates From BIIB, BMY, EXEL, Setback for VRCA

by Ekta Bagri

Regulatory and pipeline updates from pharma giants like Biogen (BIIB) and Bristol Myers (BMY) have been some of the key highlights in the biotech sector during the past week.

Verrica (VRCA) Gets CRL From the FDA for Skin Disease Drug

by Zacks Equity Research

Verrica (VRCA) suffers a setback yet again as the FDA issues a CRL for its lead product candidate VP-102. Consequently, shares are trading down.

Verrica's (VRCA) Skin Disease Candidate Approval Gets Delayed

by Zacks Equity Research

Verrica's (VRCA) NDA for lead candidate, VP-102, a drug-device combination treatment for skin disease, molluscum, is under review. FDA delays decision on potential approval for the candidate by three months.

Verrica (VRCA) in Focus: Stock Moves 8.9% Higher

by Zacks Equity Research

Verrica (VRCA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Pacira's (PCRX) Exparel Meets Key Goals in C-Section Study

by Zacks Equity Research

Pacira's (PCRX) phase IV CHOICE study on its lead drug Exparel in patients undergoing Cesarean section attains the primary as well as key secondary endpoints.

FibroGen Begins Study on Roxadustat for Chemo-Induced Anemia

by Zacks Equity Research

FibroGen (FGEN) doses the first patient in a phase II study on roxadustat for the treatment of anemia in cancer patients receiving chemotherapy.

Will Verrica Pharmaceuticals Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Verrica Pharmaceuticals.

FibroGen's Evrenzo Gets Nod in Japan for Anemia with CKD

by Zacks Equity Research

FibroGen's (FGEN) Evrenzo (roxadustat) wins a marketing approval in Japan for treating anemia caused by chronic kidney disease in dialysis-dependent patients.

Kinjel Shah headshot

Buy These 7 Small Drugmakers to Boost Your Portfolio's Health

by Kinjel Shah

Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.

Kinjel Shah headshot

Small Drug Stock Outlook: Innovation Holds the Key to Growth

by Kinjel Shah

Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.

Verrica (VRCA) Catches Eye: Stock Jumps 6.9%

by Zacks Equity Research

Verrica (VRCA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.